Source: Citybizlist

AavantiBio: Solid Biosciences Acquires AavantiBio

CHARLESTOWN, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) - Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing... Read More The post Solid Biosciences Acquires AavantiBio appeared first on citybiz.

Read full article »

AavantiBio's Competitors | AavantiBio's News | AavantiBio's Financials

Followers on Owler

650

Est. Annual Revenue

$5.0-25M

Est. Employees

25-100

President & CEO

Bo Cumbo

CEO Approval Rating

89/100

AavantiBio is a Massachusetts-based biotechnology company that develops gene therapies for the treatment of cardiac and central nervous system dysfunctions.